Ul­tragenyx adds new CMO with in­ter­nal pro­mo­tion; Au­to­lus CFO to leave for Mor­phoSys — but not quite yet

As Ul­tragenyx looks to use the ac­cel­er­at­ed ap­proval path­way for an in­creas­ing num­ber of rare dis­ease drugs, the com­pa­ny has pro­mot­ed Er­ic Crombez to EVP and chief med­ical of­fi­cer, ef­fec­tive May 1.

Crombez, who pre­vi­ous­ly served as CMO for gene ther­a­py and in­born er­rors of me­tab­o­lism, joined Ul­tragenyx fol­low­ing its $138 mil­lion ac­qui­si­tion of Di­men­sion Ther­a­peu­tics in No­vem­ber 2017. Since Jan­u­ary 2020, he’s al­so served in a non-vot­ing role as in­dus­try rep­re­sen­ta­tive on the FDA’s Cel­lu­lar, Tis­sue, and Gene Ther­a­pies Ad­vi­so­ry Com­mit­tee.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER